Anti-CD19/BCMA CAR NK cells is named as a drug or biological intervention in 3 clinical trials in our China trial register, 3 of which are recruiting. The lead sponsor is The Children's Hospital of Zhejiang University School of Medicine. Registered phase: Phase EARLY_PHASE1. Conditions studied include Autoimmune Diseases; Paediatric B Cell-related Autoimmune Diseases; CAR.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06792799 | Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease (ClinicalTrials.gov ↗) Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome |
Phase EARLY_PHASE1 | Recruiting |
| NCT07283315 | Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases Paediatric B Cell-related Autoimmune Diseases, Autoimmune Diseases, CAR |
Phase EARLY_PHASE1 | Recruiting |
| NCT07490041 | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases (ClinicalTrials.gov ↗) Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE) |
Phase EARLY_PHASE1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Autoimmune Diseases | 2 |
| Paediatric B Cell-related Autoimmune Diseases | 1 |
| CAR | 1 |
| Systemic Lupus Erthematosus | 1 |
| Multi-Drug Resistant Nephrotic Syndrome | 1 |
| IgAN - IgA Nephropathy | 1 |
| Rheumatic Diseases | 1 |
| Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese) | 1 |
| Systemic Lupus Erythematosus (SLE) | 1 |
| Connective Tissue Disease-associated Interstitial Lung Disease | 1 |
| Lead sponsor | Trials |
|---|---|
| The Children's Hospital of Zhejiang University School of Medicine | 3 |
| Register | Anti-CD19/BCMA CAR NK cells trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anti-CD19/BCMA CAR NK cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anti-CD19/BCMA CAR NK cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.